|1.||Imbimbo, Bruno P: 4 articles (03/2014 - 11/2010)|
|2.||Solfrizzi, Vincenzo: 4 articles (03/2014 - 11/2010)|
|3.||Panza, Francesco: 4 articles (03/2014 - 11/2010)|
|4.||Tabira, Takeshi: 4 articles (11/2011 - 11/2009)|
|5.||Cribbs, David H: 4 articles (04/2010 - 02/2005)|
|6.||Logroscino, Giancarlo: 3 articles (03/2014 - 12/2011)|
|7.||Holmes, Clive: 3 articles (09/2013 - 04/2003)|
|8.||Nicoll, James A R: 3 articles (09/2013 - 04/2003)|
|9.||Pilotto, Alberto: 3 articles (02/2012 - 11/2010)|
|10.||Seripa, Davide: 3 articles (02/2012 - 11/2010)|
09/01/2011 - "Follow-up studies demonstrated that AN1792 could not improve cognitive functions, although senile plaques were cleared. "
05/01/2010 - "Clearance of amyloid plaques upon immunization with AN1792 effectively improves a morphological measure of neurite abnormality in the hippocampus. "
11/01/2011 - "Some patients who developed tissue amyloid plaque immuno-reactive (TAPIR) antibody showed slower decline after AN-1792 vaccination. "
01/01/2010 - "Although in some cases the apparent removal of amyloid plaques by AN-1792 was impressive, proportionate alterations in the clinical progression of AD were not evident. "
02/01/2010 - "Surprisingly, although AN-1792 cleared senile plaque amyloid, it showed no benefit in humans. "
09/01/2012 - "AN-1792 showed promising results with regards to Aβ clearance and cognitive function improvement, but also exhibited an increased risk of Th1 mediated meningoencephalitis. "
01/01/2015 - "In the phase IIa AN1792 trial, 6% of patients who received the vaccination were diagnosed with meningoencephalitis as an adverse effect. "
01/01/2015 - "Clinical Aβ vaccination trial AN1792 was interrupted due to the development in 6 % of the patients of meningoencephalitis likely involving pro-inflammatory CD4(+) T cells. "
11/01/2005 - "The second trial of vaccine, AN1792, for Alzheimer's patients was halted because of meningoencephalitis found in 6% of patients and one autopsy case was reported. "
02/01/2005 - "The cause of the meningoencephalitis in the patients that received the vaccine has not been definitively determined; however, analysis of two case reports from the AN-1792 vaccine trial suggest that the meningoencephalitis may have been caused by a T cell-mediated autoimmune response, whereas production of anti-Abeta Abs may have been therapeutic to the AD patients. "
|3.||Alzheimer Disease (Alzheimer's Disease)
08/26/2008 - "An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease."
11/06/2007 - "An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease."
05/01/2010 - "Hippocampal sections from five patients with Alzheimer's disease enrolled in the AN1792 Phase 2a trial were compared with those from 13 non-immunized Braak-stage and age-matched patients with Alzheimer's disease, and eight age-matched non-demented controls. "
11/06/2007 - "In a randomized trial of AN1792 vaccine against A beta in Alzheimer disease (AD), only 20% of vaccine recipients had an anti-AN1792 antibody response. "
07/19/2008 - "Nine of the deceased patients, all in the AN1792 group, had given consent for post-mortem analysis; one of these who did not die with Alzheimer's disease was excluded. "
|5.||Encephalitis (Encephalitis, Rasmussen)
08/01/2012 - "However, human clinical trials of vaccination with synthetic Aβ(AN1792), were halted due to brain inflammation, presumably induced by T cell-mediated immune response. "
10/14/2005 - "Human clinical trials of vaccination with synthetic Abeta (AN1792), however, were halted due to brain inflammation, presumably induced by T cell-mediated immune responses. "
04/01/2004 - "An aseptic meningo-encephalitis was reported in 5 % of patients included in a clinical trial in which a vaccine containing Abeta (42) peptide (AN1792) was administered intramuscularly. "
01/11/2005 - "The authors report a patient with Alzheimer disease (AD) without encephalitis who was immunized with AN-1792 (an adjuvanted formulation of Abeta-42). "
01/01/2014 - "Furthermore, to determine the safety of the coimmunization vaccine, we used an induced Aβ42-EAE model to mimic the meningoencephalitis that happened in the AN-1792 vaccine clinical phase II trial and tested whether the coimmunization vaccine could ameliorate T-cell-mediated brain inflammation. "
|1.||Amyloid (Amyloid Fibrils)
|6.||Scavenger Receptors (Scavenger Receptor)
|7.||Complement C1q (C1q Complement)
|10.||Immunoglobulin G (IgG)